Press Release February 1, 2021

OncoSec Medical Closes $42 Million Public Offering of Common Stock

Alston & Bird client OncoSec Medical Incorporated, a late-stage biotechnology company, has closed a public offering of common stock that raised approximately $42 million.

The company will use the net proceeds from the offering for continued product development; potential in-license, acquisition, and development and commercialization of other pharmaceutical products; and general corporate purposes.
 
Based in Pennington, NJ, and listed on Nasdaq, OncoSec focuses on designing, developing, and commercializing novel treatments that use the body’s immune system to fight cancer.

Representing OncoSec in the public offering is an Alston & Bird team led by partner Matt Mamak and associates Robyn Downing and Laura Giambalvo (Corporate & Business Transactions) and partner Bryan Skelton and patent agent Kirk Ekena (Intellectual Property).
 
Media Contact
Nicholas Clarke
Communications Director
Phone: 212.210.1222

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.